SRP3132

Osteoprotegerin (OPG) human

recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture

• Synonym(e): OCIF (osteoclastogenesis inhibitory factor), OPG, TNFRSF11B, TR1
• UNSPSC-Code: 12352202
• NACRES: NA.32

Eigenschaften

• Biologische Quelle: human
• Rekombinant: expressed in E. coli
• Assay: ≥98% (HPLC); ≥98% (SDS-PAGE)
• Form: lyophilized
• Mol-Gew.: 20.0 kDa
• Verpackung: pkg of 50 μg
• Methode(n): cell culture | mammalian: suitable
• Verunreinigungen: <0.1 EU/μg endotoxin, tested
• Farbe: white to off-white
• UniProt-Hinterlegungsnummer: O00300
• Versandbedingung: wet ice
• Lagertemp.: −20°C
• Angaben zum Gen: human ... TNFRSF11B(4982)

Beschreibung

Allgemeine Beschreibung

Osteoprotegerin (OPG) is a member of the TNFR (tumor necrosis factor receptor) superfamily that can act as a decoy receptor for RANKL (receptor activator of nuclear factor κ-B ligand). The gene is mapped to human chromosome 8q24. The primary structure of OPG protein consists of seven distinct domains, four of which corresponds to the extracellular cysteine-rich domains of TNFR proteins and constitutes the soluble OPG. OPG is expressed in a wide variety of tissues including adult heart, lung, kidney, liver, spleen, prostate, lymph node and bone marrow. It is secreted both as a monomeric and a dimeric protein. Recombinant human OPG is a soluble 20kDa protein containing 174 amino acid residues.

Anwendung

Osteoprotegerin (OPG) human has been used as a supplement in human cell culture during cytokine production.

Biochem./physiol. Wirkung

Binding of soluble osteoprotegerin (OPG) to sRANKL (soluble receptor activator of nuclear factor κ-B ligand) inhibits osteoclastogenesis by interrupting the signaling between stromal cells and osteoclastic progenitor cells, thereby leading to excess accumulation of bone and cartilage. Changes in the level of serum OPG are associated with atherosclerosis and cardiovascular disorders. It might also be associated with malignancy and plays a regulatory role in multiple myeloma, prostate, breast, bladder and gastric carcinoma.

Sequenz

METFPPKYLH YDEETSHQLL CDKCPPGTYL KQHCTAKWKT VCAPCPDHYY TDSWHTSDEC LYCSPVCKEL QYVKQECNRT HNRVCECKEG RYLEIEFCLK HRSCPPGFGV VQAGTPERNT VCKRCPDGFF SNETSSKAPC RKHTNCSVFG LLLTQKGNAT HDNICSGNSE STQK

Physikalische Form

Lyophilized from 10 mM Tris pH, 7.5 + 75 mM NaCl.

Rekonstituierung

Centrifuge the vial prior to opening. Reconstitute in 5 mM Tris, pH 7.5 to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable